BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Khayami R, Hashemi SR, Kerachian MA. Role of aldo-keto reductase family 1 member B1 (AKR1B1) in the cancer process and its therapeutic potential. J Cell Mol Med 2020;24:8890-902. [PMID: 32633024 DOI: 10.1111/jcmm.15581] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Li Q, Wang R, Yang Z, Li W, Yang J, Wang Z, Bai H, Cui Y, Tian Y, Wu Z, Guo Y, Xu J, Wen L, He J, Tang F, Wang J. Molecular profiling of human non-small cell lung cancer by single-cell RNA-seq. Genome Med 2022;14:87. [PMID: 35962452 DOI: 10.1186/s13073-022-01089-9] [Reference Citation Analysis]
2 Bailly C. Moving toward a new horizon for the aldose reductase inhibitor epalrestat to treat drug-resistant cancer. Eur J Pharmacol 2022;931:175191. [PMID: 35964660 DOI: 10.1016/j.ejphar.2022.175191] [Reference Citation Analysis]
3 Zhang X, Li Y, Hu P, Xu L, Qiu H. Identification of molecular patterns and prognostic models of epithelial–mesenchymal transition- and immune-combined index in the gastric cancer. Front Pharmacol 2022;13:958070. [DOI: 10.3389/fphar.2022.958070] [Reference Citation Analysis]
4 Chompunud Na Ayudhya C, Graidist P, Tipmanee V. Potential Stereoselective Binding of Trans-(±)-Kusunokinin and Cis-(±)-Kusunokinin Isomers to CSF1R. Molecules 2022;27:4194. [DOI: 10.3390/molecules27134194] [Reference Citation Analysis]
5 Zhao H, Dong X, Huang T, Li X, Koundal D. A Potential Prognostic Biomarker for Glioma: Aldo-Keto Reductase Family 1 Member B1. Computational Intelligence and Neuroscience 2022;2022:1-8. [DOI: 10.1155/2022/9979200] [Reference Citation Analysis]
6 Ji J, Jin D, Xu M, Jiao Y, Wu Y, Wu T, Lin R, Zheng W, Liu Z, Jiang F, Fan Y, Xiao M. AKR1B1 promotes pancreatic cancer metastasis by regulating lysosome-guided exosome secretion. Nano Res . [DOI: 10.1007/s12274-022-4167-z] [Reference Citation Analysis]
7 Hojnik M, Šuster NK, Smrkolj Š, Sisinger D, Grazio SF, Verdenik I, Rižner TL. AKR1B1 as a Prognostic Biomarker of High-Grade Serous Ovarian Cancer. Cancers (Basel) 2022;14:809. [PMID: 35159076 DOI: 10.3390/cancers14030809] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Martinez R 3rd, Huang W, Buck H, Rea S, Defnet AE, Kane MA, Shapiro P. Proteomic Changes in the Monolayer and Spheroid Melanoma Cell Models of Acquired Resistance to BRAF and MEK1/2 Inhibitors. ACS Omega 2022;7:3293-311. [PMID: 35128241 DOI: 10.1021/acsomega.1c05361] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Dillinger T, Sheibani-Tezerji R, Pulverer W, Stelzer I, Hassler MR, Scheibelreiter J, Pérez Malla CU, Kuroll M, Domazet S, Redl E, Ely S, Brezina S, Tiefenbacher A, Rebhan K, Hübner N, Grubmüller B, Mitterhauser M, Hacker M, Weinhaeusel A, Simon J, Zeitlinger M, Gsur A, Kramer G, Shariat SF, Kenner L, Egger G. Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies. Mol Cancer 2022;21:7. [PMID: 34980142 DOI: 10.1186/s12943-021-01445-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Hermawan A, Putri H. Systematic analysis of potential targets of the curcumin analog pentagamavunon-1 (PGV-1) in overcoming resistance of glioblastoma cells to bevacizumab. Saudi Pharm J 2021;29:1289-302. [PMID: 34819791 DOI: 10.1016/j.jsps.2021.09.015] [Reference Citation Analysis]
11 Sabatier P, Beusch CM, Gencheva R, Cheng Q, Zubarev R, Arnér ESJ. Comprehensive chemical proteomics analyses reveal that the new TRi-1 and TRi-2 compounds are more specific thioredoxin reductase 1 inhibitors than auranofin. Redox Biol 2021;48:102184. [PMID: 34788728 DOI: 10.1016/j.redox.2021.102184] [Reference Citation Analysis]
12 Zhu K, Xiaoqiang L, Deng W, Wang G, Fu B. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer. Lipids Health Dis 2021;20:146. [PMID: 34706720 DOI: 10.1186/s12944-021-01554-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Dai T, Ye L, Yu H, Li K, Li J, Liu R, Lu X, Deng M, Li R, Liu W, Yang Y, Wang G. Regulation Network and Prognostic Significance of Aldo-Keto Reductase (AKR) Superfamily Genes in Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:997-1021. [PMID: 34513744 DOI: 10.2147/JHC.S323743] [Reference Citation Analysis]
14 Imran A, Tariq Shehzad M, Al Adhami T, Miraz Rahman K, Hussain D, Alharthy RD, Shafiq Z, Iqbal J. Development of coumarin-thiosemicarbazone hybrids as aldose reductase inhibitors: Biological assays, molecular docking, simulation studies and ADME evaluation. Bioorg Chem 2021;115:105164. [PMID: 34314916 DOI: 10.1016/j.bioorg.2021.105164] [Reference Citation Analysis]
15 Hojnik M, Frković Grazio S, Verdenik I, Rižner TL. AKR1B1 and AKR1B10 as Prognostic Biomarkers of Endometrioid Endometrial Carcinomas. Cancers (Basel) 2021;13:3398. [PMID: 34298614 DOI: 10.3390/cancers13143398] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
16 Kikuya M, Furuichi K, Hirao T, Endo S, Toyooka N, Ito K, Aoki S. Aldo-keto reductase inhibitors increase the anticancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia. J Pharmacol Sci 2021;147:1-8. [PMID: 34294359 DOI: 10.1016/j.jphs.2021.05.001] [Reference Citation Analysis]
17 Kovacikova L, Prnova MS, Majekova M, Bohac A, Karasu C, Stefek M. Development of Novel Indole-Based Bifunctional Aldose Reductase Inhibitors/Antioxidants as Promising Drugs for the Treatment of Diabetic Complications. Molecules 2021;26:2867. [PMID: 34066081 DOI: 10.3390/molecules26102867] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
18 Di Giuseppe F, Carluccio M, Zuccarini M, Giuliani P, Ricci-Vitiani L, Pallini R, De Sanctis P, Di Pietro R, Ciccarelli R, Angelucci S. Proteomic Characterization of Two Extracellular Vesicle Subtypes Isolated from Human Glioblastoma Stem Cell Secretome by Sequential Centrifugal Ultrafiltration. Biomedicines 2021;9:146. [PMID: 33546239 DOI: 10.3390/biomedicines9020146] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
19 Verma SK, Kumar N, Thareja S. Gaussian field-based comparative 3D QSAR modelling for the identification of favourable pharmacophoric features of chromene derivatives as selective inhibitors of ALR2 over ALR1. Struct Chem 2021;32:1289-98. [DOI: 10.1007/s11224-020-01714-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Jamialahmadi K, Azghandi M, Javadmanesh A, Zardadi M, Shams Davodly E, Kerachian MA. A DNA methylation panel for high performance detection of colorectal cancer. Cancer Genet 2021;252-253:64-72. [PMID: 33387936 DOI: 10.1016/j.cancergen.2020.12.007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Shen C, Liu J, Wang L, Liang Z, Niu H, Wang Y. Identification of metabolism-associated genes and construction of a prognostic signature in bladder cancer. Cancer Cell Int 2020;20:538. [PMID: 33292266 DOI: 10.1186/s12935-020-01627-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
22 Khayami R, Hashemi SR, Kerachian MA. Role of aldo-keto reductase family 1 member B1 (AKR1B1) in the cancer process and its therapeutic potential. J Cell Mol Med 2020;24:8890-902. [PMID: 32633024 DOI: 10.1111/jcmm.15581] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]